


# MCB 5430 midterm assignment

Bianca Mocanu



Tree folder structure of the script output

# 1 ChIP-seq processing, alignment and display

## 1.1 Pipeline

The shell script used in processing all of the data in this midterm can be found [here](#).

## 1.2 Summary table

The mapping of the reads has been done with the -m 1 option. Therefore, the "reads with at least one reported alignment" field in the log file refers to the number of uniquely mapped reads that fulfilled the mapping parameters. Table 1 displays the summary of the reads alignment step of the pipeline.

**Table 1.** Summary table for the alignment step of the pipeline. Reads total refers to the number of fastq reads that passed the preprocessing steps of the pipeline. "# and % unique" display the number and the percentage of uniquely mapped reads. "# and % multiple" display the number and the percentage of multiply mapped reads that got discarded due to the constraints of the mapping parameter -m 1. "# and % unaligned" display the number and percentage of reads that did not align to the hg19 genome.

Sample	# reads total	# unique	# multiple	# unaligned	% unique	% multiple	% unaligned
Input	12,265,901	10,088,192	1,016,900	1,160,809	82.25	8.29	9.46
treatment A rep 1	13,164,770	10,716,882	921,317	1,526,571	81.41	7.00	11.60
treatment A rep 2	14,071,793	11,248,659	971,196	1,851,938	79.94	6.90	13.16
treatment AB rep 1	13,132,269	10,686,406	955,345	1,490,518	81.38	7.27	11.35
treatment AB rep 2	8,725,137	6,948,241	601,088	1,175,808	79.63	6.89	13.48

## 2 Genome browser shot

The genome browser PDF document displays the highest peak on Chromosome 12 and can be found [here](#).

### 3 Peak calling and analysis

The following part of the script includes the peak calling step, high confidence peak files generation and getting the peaks unique to each treatment. Since they were all typed in a single for loop, they are displayed together below (therefore the for loop ends on next page).

#### 3.1 MACS

```

158
159
160 #=====
161 # This part is for calling peaks using MACS. After peak calling, it shifts the peaks by half the "d" value
162 # that the pdf reports and creates files for genome
163 # browser use by adding the BED headers. The genome browser will display a region 300 nts upstream and
164 # downstream of the top peak found in chromosome 12.
165 #For MEME and FIMO usage, one should use the top summits from the entire set of chromosomes (w/ file
166 #provided on the server)
167 #=====
168
169 cd ..
170 echo "Calling peaks for Chromosome 12 using MACS"
171
172 if [ -s ${outPATH}peaks ]
173 then
174     cd peaks
175 else
176     mkdir peaks
177     cd peaks
178 fi
179
180 for file in $fastqfiles
181 do
182     ext=`echo $(basename $file) | cut -d "." -f 2` # generated to see file type
183     prefix=`echo $(basename $file) | cut -d "." -f 1` #creates a prefix for each fastq file that is
184     analyzed
185
186     if [ $prefix != "Input" ]
187     then
188         macs14 -t ${outPATH}${prefix}/${prefix}_chr12.sorted.bam -c ${outPATH}Input/
189         Input_chr12.sorted.bam -f BAM -n ${prefix} -g 133851895
190         Rscript ${prefix}_model.r
191         peakshift=`grep "legend" ${prefix}_model.r | tail -n 1 | cut -d "=" -f2 | cut -d "\"" -f1`
192
193         top_peak=`sort -k5nr ${prefix}_summits.bed | head -1 | cut -f2`
194         browser_start=$((top_peak - 300))
195         browser_end=$((top_peak + 300))
196
197         echo "Shifting peaks by $peakshift"
198         awk -v d=$peakshift '{printf ("%s\t%s\t%s\t%s\t%s\n", $1, $2 + (d/2), $3 - (d/2), $4, $5)}'
199         ${prefix}_peaks.bed > ${prefix}_peaks_shifted.bed
200
201         echo "Generating UCSC BED files with headers for peaks and summits"
202
203         awk -v NAME=${prefix}_peaks -v browser_start=$browser_start -v browser_end=$browser_end
204         'BEGIN { print "browser position chr12:("browser_start")-("browser_end")"
205         print "track type=bed name=\""NAME "\" description=\""NAME "\" visibility=squish
206         autoScale=on colorByStrand=\"255,0,0 0,0,255\""}
207         { print $0}' ${prefix}_peaks_shifted.bed > ${prefix}_peaks_shifted_header.bed
208
209         awk -v NAME=${prefix}_summits -v browser_start=$browser_start -v browser_end=$browser_end
210         'BEGIN { print "browser position chr12:("browser_start")-("browser_end")"
211         print "track type=bed name=\""NAME "\" description=\""NAME "\" visibility=squish
212         autoScale=on colorByStrand=\"255,0,0 0,0,255\""}
213         { print $0}' ${prefix}_summits.bed > ${prefix}_summits_header.bed
214

```

### 3.2 High confidence peaks and 2.3 Peaks specific to each treatment

```

205 # =====
206 # This part intersects the datasets to report:
207 # 1. High confidence peaks between replicates
208 # 2. Peaks specific only to treatment A or only to treatment A+B
209 # =====
210
211 sample=`echo $prefix | cut -d "_" -f1,2`
212
213 if [ -s ${sample}_rep1_peaks_shifted.bed ] && [ -s ${sample}_rep2_peaks_shifted.bed ]
214 then
215     echo "Finding high confidence peaks between replicates"
216     bedtools intersect -a ${sample}_rep1_peaks_shifted.bed -b ${sample}_rep2_peaks_shifted.bed > ${sample}_peaks_highconf.bed
217
218 # the next statement is a bit iffy because it needs the other sample high confidence peaks bed file, and
219 # it depends on the order the files are processed, but works
220
221 if [ $sample=="treatA_chip" ] && [ -s treatAB_chip_peaks_highconf.bed ]
222 then
223     bedtools intersect -v -a ${sample}_peaks_highconf.bed -b treatAB_chip_peaks_highconf.bed > ${sample}_only_peaks.bed
224 elif [ $sample=="treatAB_chip" ] && [ -s treatA_chip_peaks_highconf.bed ]
225 then
226     bedtools intersect -v -a ${sample}_peaks_highconf.bed -b treatA_chip_peaks_highconf.bed > ${sample}_only_peaks.bed
227 fi
228 fi
229
230 done | tee -a ${outPATH}logfiles/log.txt
231
232
233
234
235 cd $outPATH

```

**Observation:** The file containing peaks unique to treatment AB only is an empty file. This does not seem to be a script error - upon analysis of the peaks common to both treatments and peaks unique to treatment A, it is likely that AB peaks are a subset of A peaks. This already might mean that whatever treatment AB is, it inhibits the binding of this transcription factor to DNA.

## 4 Distribution of TF binding sites

### 4.1 Bed files with promoter, gene and intergenic sequences

For this step, TSS abbreviation of the files stands for the promoters, genes represent the genes and IGS represent the intergenic sequences. In addition to .bed files for each region type, .fasta files have been created here as well.

```

237 echo "Generating gene lists" | tee -a ${outPATH}logfiles/log_geneLists.txt
238 mkdir geneLists
239 cd geneLists
240
241
242 #=====
243 # This part processes the hg19_gencode_ENSG_geneID.bed file to retrieve the TSS, promoters, genes and
244 # intergenic regions for chromosome 12
245 #=====
246
247 # Retrieving only chromosome 12 entries:
248
249 echo "Retrieving chr12 entries" | tee -a ${outPATH}logfiles/log_geneLists.txt
250 cat $gencode | grep "chr12" > ./gencode_ENSG_geneID_chr12.txt
251
252 # Retrieving TSS - if the gene is on the + strand, start of gene is $2 => subtract 500 from $2 (start of
253 # TSS) and add 500 to $2 (end of TSS)
254 # If the gene is on the - strand, the start of the gene is $3 => add 500 to $3 (start of TSS) and subtract
255 # 500 to $3 (end of TSS)
256 # In these BED files, the smaller coordinate is always in col. 2, regardless of the strand
257
258 echo "Creating TSS only file" | tee -a ${outPATH}logfiles/log_geneLists.txt
259 awk '{if($6=="+" && $2<$3)
260 printf ("%s\t%s\t%s\t%s\t%s\t%s\n", $1, $2 - 500, $2 + 500, $4, $5, $6);
261 else if($6=="-" && $2<$3)
262 printf ("%s\t%s\t%s\t%s\t%s\t%s\n", $1, $3 - 500, $3 + 500, $4, $5, $6)
263 }' gencode_ENSG_geneID_chr12.txt > gencode_ENSG_geneID_chr12_TSS.bed
264 bedtools getfasta -name -fi $hg19 -bed gencode_ENSG_geneID_chr12_TSS.bed -fo
265 gencode_ENSG_geneID_chr12_TSS.fasta
266
267 # Retrieving genes - if the gene is on the + strand, gene region starts at $2 + 501 and ends at the $3 + 1000
268 # if the gene is on the - strand, the gene ends at $2 - 1000, starts at $3 - 501
269 # In these BED files, the smaller coordinate is always in col. 2 regardless of the strand
270
271 echo "Creating genes only file" | tee -a ${outPATH}logfiles/log_geneLists.txt
272 awk '{if($6=="+" && $2<$3)
273 printf ("%s\t%s\t%s\t%s\t%s\t%s\n", $1, $2 + 501, $3 + 1000, $4, $5, $6);
274 else if($6=="-" && $2<$3)
275 printf ("%s\t%s\t%s\t%s\t%s\t%s\n", $1, $2 - 1000, $3 - 501, $4, $5, $6)
276 }' gencode_ENSG_geneID_chr12.txt > gencode_ENSG_geneID_chr12_genes.bed
277 bedtools getfasta -name -fi $hg19 -bed gencode_ENSG_geneID_chr12_genes.bed -fo
278 gencode_ENSG_geneID_chr12_genes.fasta
279
280 # Intergenic regions - basically if it's not part of the first two - intersect with chromosome 12 file and
281 take the complement
282
283 echo "Creating IGS only file" | tee -a ${outPATH}logfiles/log_geneLists.txt
284 #creating a temporary file with both TSS and genes and creating the chromosome 12 only file size
285
286 grep chr12 $hg19chromInfo > ./chr12Info.txt
287
288 cat ./gencode_ENSG_geneID_chr12_TSS.bed >> gencode_ENSG_geneID_chr12_genesandTSS.bed
289 cat ./gencode_ENSG_geneID_chr12_genes.bed >> gencode_ENSG_geneID_chr12_genesandTSS.bed
290
291 # intersecting the file with chromosome 12
292 bedtools sort -i gencode_ENSG_geneID_chr12_genesandTSS.bed > gencode_ENSG_geneID_chr12_genesandTSS.sorted.bed
293 bedtools complement -i gencode_ENSG_geneID_chr12_genesandTSS.sorted.bed -g chr12Info.txt >
294 gencode_ENSG_geneID_chr12_IGS.bed
295 rm gencode_ENSG_geneID_chr12_genesandTSS.*
296 bedtools getfasta -name -fi $hg19 -bed gencode_ENSG_geneID_chr12_IGS.bed -fo
297 gencode_ENSG_geneID_chr12_IGS.fasta
298
299

```

## 4.2 Determining the distribution of high confidence peaks (summits) that fall into promoter, genes and intergenic sequences

This entire code block is also under the same for loop which analyzes everything down to the TOMTOM step (therefore, it's far from the 'done' line)

```

294 #=====
295 # This part analyzes the chromosome 12 summits from treatments A and A+B in order to see the distribution
296 # of the peaks that fall in the TSS, genes and IGS regions
297 # The summits files are the ones provided on /tempdata3/MCB5430/midterm/midterm/peaks folder which are the
298 # from the entire genome
299 # Also generates fasta files for MEME motif analysis and finds the MEME motifs
300 #=====
301
302 for file in $summits_highconf
303 do
304     ext=$(echo $(basename $file) | cut -d "." -f 2) # generated to see file type
305     prefix=$(echo $(basename $file) | cut -d "." -f 1) #creates a prefix for each bed file that is
306     analyzed
307     echo "Starting analysis for high confidence summits for $prefix"
308     grep chr12 $file > ${prefix}_chr12.bed
309
310     echo "Examining distribution in TSS, IGS, genes..."
311     if [ $ext=="bed" ]
312     then
313         bedtools coverage -a ${prefix}_chr12.bed -b gencode_ENSG_geneID_chr12_TSS.bed > ${prefix}_
314         _chr12_inTSS.bed
315         bedtools coverage -a ${prefix}_chr12.bed -b gencode_ENSG_geneID_chr12_IGS.bed > ${prefix}_
316         _chr12_inIGS.bed
317         bedtools coverage -a ${prefix}_chr12.bed -b gencode_ENSG_geneID_chr12_genes.bed > ${prefix}_
318         _chr12_ingenes.bed
319
320         awk '{if($9!="0.00000000")
321         print $0}' ${prefix}_chr12_inTSS.bed > ${prefix}_chr12_inTSS_nozero.bed
322
323         awk '{if($9!="0.00000000")
324         print $0}' ${prefix}_chr12_ingenes.bed > ${prefix}_chr12_ingenes_nozero.bed
325
326         awk '{if($9!="0.00000000")
327         print $0}' ${prefix}_chr12_inIGS.bed > ${prefix}_chr12_inIGS_nozero.bed
328     fi
329 done

```

### 4.3 Summary table for distribution in genomic regions

Table 2 contains a summary for the section 3.2 and for MAST and FIMO. The following example calculations show how the table was compiled:

#### 1. Grey rows: determining the distribution of high confidence peaks (summits) in different genome regions

The numbers for overlapping summits for each genomic region are present in the columns starting with #. The Total represents the sum of all summits falling in promoters, genes and intergenic sequences, and the percentages are calculated by dividing the number for each genomic region by the total number of summits:

$$\% \text{ in genes} = ( \# \text{ in genes} / \# \text{ Total} ) * 100$$

e.g. For Treatment A:

$$\% \text{ in genes} = ( \# \text{ in genes} / \# \text{ Total} ) * 100$$

$$\% \text{ in genes} = ( 411 / 1032 ) * 100$$

$$\% \text{ in genes} = \mathbf{39.82}.$$

#### 2. MAST outputs: determining how many peaks have motifs (peaks being broken down by different genome regions)

Starting for example with *treatment A intergenic regions*, 117 peaks have motif 1 and 137 peaks have motif 2. The total number of peaks with motifs for treatment A is therefore  $117+137 = 254$ . To obtain the number of peaks without motifs, 254 was subtracted from the *total peaks from intergenic regions* calculated in section 3.2 (in the grey bar):

$$\begin{aligned} \# \text{ peaks with no motifs in IGS} &= \text{total } \# \text{ peaks in IGS} - \text{total } \# \text{ peaks w/ motifs in IGS} \\ \# \text{ peaks with no motifs} &= 603 - 254 = \mathbf{349} \end{aligned}$$

To further calculate the percentages, I divided the number of peaks (having a certain motif in a certain genomic region) by the total number of peaks, regardless of genomic region. For example, for the treatment A intergenic regions for motif 1, the calculations were as following:

$$\begin{aligned} \% \text{ in IGS} &= ( \# \text{ in IGS} / \# \text{ Total} ) * 100 \\ \% \text{ in IGS} &= ( 117 / 1032 ) * 100 \\ \% \text{ in IGS} &= 11.34 \end{aligned}$$

This way, by looking at a genomic region percentages column, the white part of the table is essentially a breakdown of the grey row percentage. The table can be read, for example, like this: for treatment A, 58.43% of peaks are in intergenic regions and out of 58.43 percents 11.34 of them have motif 1, 13.28 of them have motif 2 and 33.82 of them display no motif.

**Table 2.** Summary of MAST, FIMO and distribution of summits in different genomic regions. Certain features determined with either MAST, FIMO or bedtools are broken down by intergenic regions. Raw number of peaks as well as calculated percentages of the total are displayed.

	Feature	# in promoters	% in promoters	# in genes	% in genes	# in IGS	% in IGS	# Total	% peaks with motif
MAST	Treatment A	Total peaks	18	1.74	411	39.82	603	58.43	1032
		Peaks with motif 1	1	0.10	81	7.85	117	11.34	199
		Peaks with motif 2	0	0.00	92	8.91	137	13.28	229
		Peaks with motifs (1+2)	1	0.10	173	16.76	254	24.61	428
		Peaks with no motifs	17	1.65	238	23.06	349	33.82	604
MAST	Treatment A+B	Total peaks	6	3.10	79	40.93	108	55.95	193
		Peaks with motif 1	0	0.00	11	5.70	21	10.88	32
		Peaks with motif 2	0	0.00	15	7.77	17	8.81	32
		Peaks with motifs (1+2)	0	0.00	26	13.47	38	19.69	64
		Peaks with no motifs	6	3.11	53	27.46	70	36.27	129
FIMO	Treatment A	Total motif occurrences	870	0.95	41395	45.07	49576	53.98	91841
		Motif 1 in Chr. 12	354	0.39	18637	20.29	22668	24.68	41659
		Motif 2 in Chr. 12	516	0.56	22758	24.78	26908	29.30	50182
	Treatment A+B	Total motif occurrences	848	0.90	40666	43.27	52464	55.83	93978
		Motif 1 in Chr. 12	420	0.45	22033	23.44	27851	29.64	50304
		Motif 2 in Chr. 12	428	0.46	18633	19.83	24613	26.19	43674

#### 4.4 TF preferences

This transcription factor's preference for promoters or enhancers can be assessed by looking at the number of peaks falling in promoter regions and outside promoter regions. According to Table 2, for treatment A, 1.74% of the summits are in the promoter regions, while 98.25% are in genes and intergenic sequences. For treatment A+B, 3.10 % of the summits are in the promoter regions, while 96.89% of the summits are in genes and intergenic

sequences. This means that the transcription factor has a strong preference to bind **enhancers**, rather than promoters.

## 5 Identifying motifs under peaks

### 5.1 MEME

```


323
324     echo "Retrieving top 200 peaks from the entire genome"
325     sort -k5nr $file | head -n 200 > ${prefix}_top200.bed
326     bedtools slop -i ${prefix}_top200.bed -g $hg19chrominfo -b 50 > ${prefix}_top200_100bp.bed
327     bedtools getfasta -name -fi $hg19 -bed ${prefix}_top200_100bp.bed -fo ${prefix}_top200_100bp.fasta
328
329     echo "Finding motifs with MEME for $prefix"
330
331     if [ ${prefix} == "treatA_summits" ]
332     then
333         meme ${prefix}_top200_100bp.fasta -oc ${prefix}_meme_OUT_FOLDER -bfile $TSSbackground -dna -
334         nmotifs 2 -minw 10 -maxw 18 -revcomp -mod anr
335     else
336         meme ${prefix}_top200_100bp.fasta -oc ${prefix}_meme_OUT_FOLDER -bfile $TSSbackground -dna -
337         nmotifs 2 -minw 12 -maxw 14 -revcomp -mod anr
338     fi

```


Using the code block above, the following motifs have been found (not displaying the reverse complements):

#### Treatment A

##### Motif 1:




##### Motif 2:





## Treatment A+B

## Motif 1:



## Motif 2:



## 5.2 MAST

```

337 # =====
338 # This part generates fasta sequences for the chromosome 12 TSS, genes and IGS and returns how many of
339 # each display the motifs identified with MEME
340 # (this is done using MAST). It also scans the entire chromosome 12 for motif occurrences (regardless of
341 # them being in peaks or not, using FIMO)
342 # =====
343
344 # The starting files are the three summits files with peaks in TSS, IGS and genes. They need to be
345 # expanded 50 bps each way and then converted to multi fasta
346
347 echo "Examining the motif occurrence within chromosome 12 IGS/TSS/genes summits"
348 echo "Generating fasta files for each region"
349 bedtools slop -i ${prefix}_chr12_inIGS_nozero.bed -g chr12Info.txt -b 50 > ${prefix}_
350 _chr12_inIGS_100bp.bed
351 bedtools slop -i ${prefix}_chr12_inTSS_nozero.bed -g chr12Info.txt -b 50 > ${prefix}_
352 _chr12_inTSS_100bp.bed
353 bedtools slop -i ${prefix}_chr12_ingenes_nozero.bed -g chr12Info.txt -b 50 > ${prefix}_
354 _chr12_ingenes_100bp.bed
355
356 bedtools getfasta -name -fi $hg19 -bed ${prefix}_chr12_inIGS_100bp.bed -fo ${prefix}_
357 _chr12_inIGS_100bp.fasta
358 bedtools getfasta -name -fi $hg19 -bed ${prefix}_chr12_inTSS_100bp.bed -fo ${prefix}_
359 _chr12_inTSS_100bp.fasta
360 bedtools getfasta -name -fi $hg19 -bed ${prefix}_chr12_ingenes_100bp.bed -fo ${prefix}_
361 _chr12_ingenes_100bp.fasta
362
363 #MAST syntax for each file:
364 echo "Searching for MEME motifs in chromosome 12 peaks"
365 mast ${prefix}_meme_OUT_FOLDER/meme.txt ${prefix}_chr12_inIGS_100bp.fasta -oc ${prefix}_
366 _IGS_mast_OUT_FOLDER
367 mast ${prefix}_meme_OUT_FOLDER/meme.txt -hit_list ${prefix}_chr12_inIGS_100bp.fasta -oc ${prefix}_
368 _IGS_mast_OUT_FOLDER > ${prefix}_IGS_mast_OUT_FOLDER/list_mast_hits.txt
369
370 mast ${prefix}_meme_OUT_FOLDER/meme.txt ${prefix}_chr12_inTSS_100bp.fasta -oc ${prefix}_
371 _TSS_mast_OUT_FOLDER
372 mast ${prefix}_meme_OUT_FOLDER/meme.txt -hit_list ${prefix}_chr12_inTSS_100bp.fasta -oc ${prefix}_
373 _TSS_mast_OUT_FOLDER > ${prefix}_TSS_mast_OUT_FOLDER/list_mast_hits.txt
374
375 mast ${prefix}_meme_OUT_FOLDER/meme.txt ${prefix}_chr12_ingenes_100bp.fasta -oc ${prefix}_
376 _genes_mast_OUT_FOLDER
377 mast ${prefix}_meme_OUT_FOLDER/meme.txt -hit_list ${prefix}_chr12_ingenes_100bp.fasta -oc ${prefix}_
378 _genes_mast_OUT_FOLDER > ${prefix}_genes_mast_OUT_FOLDER/list_mast_hits.txt
379

```

### 5.3 FIMO

```

365 #FIMO
366
367 echo "Generating chromosome 12 background file for FIMO"
368 fasta-get-markov $chr12 > chr12_bkgnd.txt
369
370 echo "Using FIMO on Chromosome 12 (whole)"
371 fimo --oc ${prefix}_Chr12_all_fimo_OUT_FOLDER --bgfile chr12_bkgnd.txt ${prefix}_meme_OUT_FOLDER/
372 meme.txt $chr12
373
374 echo "Using FIMO on Chromosome 12 IGS sequences"
375 fimo --oc ${prefix}_IGS_fimo_OUT_FOLDER --bgfile chr12_bkgnd.txt ${prefix}_meme_OUT_FOLDER/
376 meme.txt gencode_ENSG_geneID_chr12_IGS.fasta
377
378 echo "Using FIMO on Chromosome 12 TSS sequences"
379 fimo --oc ${prefix}_TSS_fimo_OUT_FOLDER --bgfile chr12_bkgnd.txt ${prefix}_meme_OUT_FOLDER/
380 meme.txt gencode_ENSG_geneID_chr12_TSS.fasta
381
382 echo "Using FIMO on Chromosome 12 gene encoding sequences"
383 fimo --oc ${prefix}_genes_fimo_OUT_FOLDER --bgfile chr12_bkgnd.txt ${prefix}_meme_OUT_FOLDER/
384 meme.txt gencode_ENSG_geneID_chr12_genes.fasta
385
386 echo "FIMO analysis done!"
387
388 echo "Reformatting FIMO outputs to .bed"
389
390 awk 'NR>1 {printf("%s\t%s\t%s\t%s\t%s\t%s\n", $2, $3, $4, $9, $7, $5)
391 }' ${prefix}_Chr12_all_fimo_OUT_FOLDER/fimo.txt > ${prefix}_Chr12_all_fimo_OUT_FOLDER/fimo_chr12.bed
392
393 awk 'NR>1 {printf("%s\t%s\t%s\t%s\t%s\t%s\n", $2, $3, $4, $9, $7, $5)
394 }' ${prefix}_IGS_fimo_OUT_FOLDER/fimo.txt > ${prefix}_IGS_fimo_OUT_FOLDER/fimo_IGS.bed
395
396 awk 'NR>1 {printf("%s\t%s\t%s\t%s\t%s\t%s\n", $2, $3, $4, $9, $7, $5)
397 }' ${prefix}_TSS_fimo_OUT_FOLDER/fimo.txt > ${prefix}_TSS_fimo_OUT_FOLDER/fimo_TSS.bed
398
399 awk 'NR>1 {printf("%s\t%s\t%s\t%s\t%s\t%s\n", $2, $3, $4, $9, $7, $5)
400 }' ${prefix}_genes_fimo_OUT_FOLDER/fimo.txt > ${prefix}_genes_fimo_OUT_FOLDER/fimo_genes.bed

```

In order to generate Table 2 statistics for FIMO, I used pipes to process the fimo.txt file and to find out out of the two motifs, how many occurrences are for motif 1 and how many are for motif 2, for each treatment. I then checked that the sum of the two is consistent with how many motif occurrences FIMO reports in the html file. E.g.

```
cat fimo.txt | cut -f 1 | grep 1 | wc -l    # for motif 1
```

```
cat fimo.txt | cut -f 1 | grep 2 | wc -l # for motif 2
```

#### Provide an explanation for why not all of your peaks have identified motifs.

As observed in Table 2, only 41.47% of the treatment A peaks display one of the two motifs identified using MEME. Likewise, for treatment A+B, only 33.16% of the peaks have a motif. The reasons why we identify peaks without motif can be the following:

1. According to the chosen MEME options, I looked for the best two motifs only - there could be more than two and the percentages of peaks with a motif might be higher than these numbers.
2. Transcription factors, before any sequence specificity, have DNA binding domains, which causes them to be bound to DNA / chromatin even when not active.
3. Many transcription factors are ligand-dependent, which is a great way to finely modulate the regulation of a set of genes in a ligand concentration dependent manner. Different concentrations of ligands can result in various conformational changes for the transcription factors which can bind different DNA sequences in return.

#### What do the results tell about the likelihood of the TF finding its motif?

According to the FIMO outcomes (Table 2), there is an overwhelming amount of motif sequences the transcription factor could bind on Chromosome 12. By examining the percentages, for example in treatment A+B, it also appears that the proportion of peaks

found in e.g. intergenic sequences (55.95%) is about the same as the proportion of motifs found in intergenic sequences in the genome (53.98 and 55.83% of motifs found on Chromosome 12 are in intergenic sequences).

This is obviously different from a situation where there would be very few motifs in the genome and the transcription factor would find them against all odds. This transcription factor seems to be *statistically favored to encounter its motifs*, but the abundance of motifs makes it *unlikely that the transcription factor finds its way to perform its function, e.g. upregulate a certain gene by binding to a particular enhancer*. We indeed observe it does not bind very many of these motifs, despite their abundance.

The reasons are plenty - it could be a matter of DNA accessibility (perhaps these motifs are tightly bound by histones which have repressive marks, especially in intergenic sequences), or it could be that the transcription factor generally lies at the end of a signaling cascade and its binding to the targets depends on other effector molecules as well, and not on the DNA sequence alone. This adds another degree of complexity which FIMO cannot account for.

## 5.4 TomTom

```
394 echo "Looking in JASPAR MEME databases (tomtom)"
395 tomtom -eps -m 1 -o ${prefix}_tomtom_OUT ${prefix}_meme_OUT_FOLDER/meme.txt $jaspar_meme
396
```

According to the TomTom search, for treatment A, there are the following candidate transcription factors:

Name MA0258.1	Name MA0112.1
Alt. Name ESR2	Alt. Name ESR1
Database jaspar.meme	Database jaspar.meme
p-value 5.63649e-09	p-value 8.99539e-09

For treatment A+B, there are the following transcription factors:

Name MA0112.2	Name MA0258.1	Name MA0066.1
Alt. Name ESR1	Alt. Name ESR2	Alt. Name PPARG
Database jaspar.meme	Database jaspar.meme	Database jaspar.meme
p-value 3.00279e-10	p-value 2.0445e-08	p-value 2.46812e-07

## 6 Final Question: What factor did Billy ChIP, and what were each of the treatments?

From the TomTom hits above, one can confidently say that the antibody Billy did was against the Estrogen Receptor protein ESR1 or ESR2. According to the uniprot database, the following are known about the Estrogen Receptor <sup>[3]</sup> :

ESR1 binds DNA as a homodimer and it can form heterodimers with ESR2 as well. Binding is followed by a phosphorylation event on both of the monomer subunits.

Generally, ESR is stabilized by phosphorylation (and protected from proteosomal degradation). ESR activity is modulated by signaling pathway kinases that phosphorylate ESR1 as well as its interacting partners.

ESR has three domains - a modulating N-terminal domain, a DNA binding domain (2 zinc fingers) and a C-terminal ligand binding domain. The N-terminal domain can transactivate in a ligand independent manner, while the C-terminal can transactivate in a ligand dependent manner. Transcription is canonically activated through the C-terminal domain by binding of estrogen. As a result of ligand binding, ESR1 associates with a network of coactivators and binds to estrogen responsive elements.

Various mutations of ESR C-terminal domain are associated with disease. Several mutations result in estrogen resistance disease, where the variants have greatly reduced canonical activity in the presence of elevated estrogen levels. The non-classical activity of the mutants (through the estrogen independent domain) is greatly enhanced and this promotes tumor development and progression.<sup>[1]</sup>

As seen in Table 2, the total number of peaks for treatment A is 1032, while the number of peaks for treatment A+B is 193. An observation described in section 2.3 shows that the peaks in treatment A+B are a subset of treatment A, which means that the addition of B reagent results in a decreased binding of ESR 1 to the responsive elements. All things considered, for Chromosome 12 peaks, this is a 81.2% decrease in binding.

Assuming that the cell lines Billy has used have the wild type estrogen receptor, treatment A could be estrogen itself, while B can be anything that inhibits ESR1.

One popular treatment for breast cancer cells with wild type ESR1 is an aromatase inhibitor. However, this is not a good choice because aromatase uses body levels of androgen hormones as a substrate and only the production of estrogen in a body context would be lowered.

Another candidate for treatment B is tamoxifen, which is a competitor of estrogen in binding to ESR1 and an antagonist. However, tamoxifen binding to ESR1 still results in binding to DNA and repression of transcription, which in a ChIP-seq experiment would not result in differential binding of ESR1 to DNA - the peaks would still come up<sup>[2]</sup>.

It is safe to assume interfering with phosphorylation will result in destabilizing the ESR1 homodimers or ESR1/2 heterodimers that can bind to DNA. Treatment A could be estrogen, while treatment B could be a kinase inhibitor which would show that even in the presence of estrogen, ESR1 cannot bind to the responsive elements. In addition, repressing phosphorylation in general affects the entire signaling pathway and prevents ESR1 interaction with DNA via both ligand dependent and independent domains.

**REFERENCES**

[1] Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R (2015) *ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer* Nat Rev Clin Oncol. 12(10): 573–583.

[2] Wang DY, Fulthorpe R, Liss SN, Edwards EA (2004). *Identification of Estrogen-Responsive Genes by Complementary Deoxyribonucleic Acid Microarray and Characterization of a Novel Early Estrogen-Induced Gene: EEIG1* Molecular Endocrinology, Volume 18, Issue 2, Pages 402–411.

Internet resources:

[3] [www.uniprot.org/uniprot/P03372](http://www.uniprot.org/uniprot/P03372) (Retrieved on Nov. 5, 2017)